Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ALVR NASDAQ:EXOZ NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.40-3.1%$1.39$0.86▼$3.36$84.50M0.14318,909 shs71,470 shsALVRAlloVir$4.68+0.9%$2.85$7.96▼$24.15$23.60M0.6315,685 shs87,582 shsEXOZeXoZymes$12.03+2.3%$9.96$8.50▼$23.99$100.90MN/A13,731 shs3,153 shsIMUXImmunic$0.89+3.5%$0.89$0.56▼$2.11$87.50M1.441.24 million shs671,617 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+2.13%+5.88%+5.88%+26.32%-40.98%ALVRAlloVir+0.43%+13.73%+73.78%+50.65%-72.86%EXOZeXoZymes-2.00%+21.36%+19.51%-10.57%+1,175,999,900.00%IMUXImmunic+3.29%+7.30%-1.70%-1.46%-38.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.40-3.1%$1.39$0.86▼$3.36$84.50M0.14318,909 shs71,470 shsALVRAlloVir$4.68+0.9%$2.85$7.96▼$24.15$23.60M0.6315,685 shs87,582 shsEXOZeXoZymes$12.03+2.3%$9.96$8.50▼$23.99$100.90MN/A13,731 shs3,153 shsIMUXImmunic$0.89+3.5%$0.89$0.56▼$2.11$87.50M1.441.24 million shs671,617 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+2.13%+5.88%+5.88%+26.32%-40.98%ALVRAlloVir+0.43%+13.73%+73.78%+50.65%-72.86%EXOZeXoZymes-2.00%+21.36%+19.51%-10.57%+1,175,999,900.00%IMUXImmunic+3.29%+7.30%-1.70%-1.46%-38.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$7.00386.11% UpsideALVRAlloVir 0.00N/AN/AN/AEXOZeXoZymes 0.00N/AN/AN/AIMUXImmunic 3.20Buy$8.33872.04% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, IMUX, ABOS, and EXOZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ABOSAcumen PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.008/8/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/25/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/AALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AEXOZeXoZymesN/AN/AN/AN/A$1.25 per shareN/AIMUXImmunicN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)ALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/A-134.50%-81.63%N/AIMUXImmunic-$100.51M-$0.94N/AN/AN/AN/A-461.46%-217.16%11/6/2025 (Estimated)Latest ALVR, IMUX, ABOS, and EXOZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54-$0.68-$0.14-$0.68N/AN/A8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A8/7/2025Q2 2025IMUXImmunic-$0.18-$0.20-$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.265.975.97ALVRAlloVirN/A86.7886.78EXOZeXoZymes0.016.196.19IMUXImmunicN/A2.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ALVRAlloVir66.05%EXOZeXoZymesN/AIMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%ALVRAlloVir32.07%EXOZeXoZymes72.41%IMUXImmunic4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million56.27 millionOptionableALVRAlloVir1105.04 million3.43 millionOptionableEXOZeXoZymes298.39 million2.31 millionN/AIMUXImmunic7098.65 million94.11 millionOptionableALVR, IMUX, ABOS, and EXOZ HeadlinesRecent News About These CompaniesImmunic receives notice of allowance for vidofludimus calcium patentSeptember 9 at 1:18 PM | msn.comImmunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MSSeptember 9 at 8:56 AM | proactiveinvestors.comImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisSeptember 9 at 6:30 AM | prnewswire.comB. Riley Weighs in on Immunic's Q3 Earnings (NASDAQ:IMUX)September 6, 2025 | marketbeat.comResearch Analysts Set Expectations for Immunic Q3 EarningsSeptember 5, 2025 | americanbankingnews.comImmunic to Participate in Investor and Scientific Conferences in SeptemberSeptember 4, 2025 | prnewswire.comCan Immunic (NASDAQ:IMUX) Afford To Invest In Growth?September 1, 2025 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from BrokeragesAugust 27, 2025 | marketbeat.com1,059,484 Shares in Immunic, Inc. $IMUX Acquired by Aberdeen Group plcAugust 24, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for ImmunicAugust 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for Immunic Q1 Earnings?August 12, 2025 | marketbeat.comWilliam Blair Predicts Immunic's Q1 Earnings (NASDAQ:IMUX)August 12, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Announces Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comImmunic, Inc. (IMUX) latest stock news and headlines – Yahoo FinanceAugust 10, 2025 | sg.finance.yahoo.comImmunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIAugust 9, 2025 | proactiveinvestors.comImmunic (IMUX) Q2 Loss Widens 25%August 8, 2025 | theglobeandmail.comImmunic advances MS drug program with Phase 3 trials fully enrolledAugust 7, 2025 | proactiveinvestors.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ...August 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comImmunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS TrialJuly 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, IMUX, ABOS, and EXOZ Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.40 -0.05 (-3.13%) As of 11:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.AlloVir NASDAQ:ALVR$4.68 +0.04 (+0.86%) As of 09/9/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.eXoZymes NASDAQ:EXOZ$12.03 +0.27 (+2.30%) As of 11:45 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Immunic NASDAQ:IMUX$0.89 +0.03 (+3.46%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
